Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial
![Photo: Muusfoto / Gubra / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13196018.ece/ALTERNATES/schema-16_9/doc7h2ae7skvgjeml1c2l5.jpg)
The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.